Collegium Pharmaceutical Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $808.2M+28.0% YoYTTM through 30 Jun 2026
Net Income $47.9M-30.7% YoYTTM through 30 Jun 2026
Free Cash Flow $328.3MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 60.0% |
| EBITDA Margin | 19.6% |
| Operating Margin | 19.5% |
| Net Margin | 5.9% |
Returns
20.8%ROE
3.8%ROA
4.8%ROIC
Balance Sheet Health
Debt / Equity2.68x
Current Ratio1.03x
Net Debt$422.6M
Cash & Equivalents$129.5M
Quality Metrics
Altman Z-Score0.80
Piotroski F-Score5 / 9
FCF Margin40.6%
Rule of 4044.2
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $780.6M
Diluted EPS$1.24TTMFY2025: $1.73
Dividend
No dividend
Capital Allocation
Capex Intensity0.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Pain Portfolio | $631.7M | +6.0% | View detailsExpected to deliver durable revenues and generate predictable cash flows |
| ADHD Business (JORNAY PM) | $148.9M | +48.0% | View detailsExpected to drive significant growth in 2026 with net revenue guided at $190M-$200M |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.